_2020091018165303jzv.jpg "Decoding The World Of ETF")
My Account
Nov 23, 2020 01:53 PM IST Gland Pharma's IPO subscription response was tepid compared to the recent entrants. However, it closed 21 percent higher than the issue price of Rs 1500. Let's find out what should investors do post the listing
Nov 23, 2020 09:42 AM IST A vertically-integrated model and a strong regulatory compliance history with focus on R&D are tailwinds for Gland Pharma
Nov 20, 2020 06:08 PM IST Gland Pharma traded with volume of 7,87,955 equity shares on the BSE and 1,13,10,647 shares on the NSE. The market capitalisation stood at Rs 29,725 crore.
Nov 20, 2020 01:21 PM IST Experts have a positive long-term view on the stock, given the company's strong financials and hold in the injectable business.
Nov 20, 2020 10:00 AM IST Fosun Singapore and Shanghai Fosun Pharma are the promoters of the company. Their shareholding reduced to 58 percent in the company from 74 percent post issue.
Nov 19, 2020 04:08 PM IST Gland Pharma has a track record of growth and profitability from a diversified revenue base with healthy cash flows. Also, fundamentals of the company look strong, said Astha Jain of Hem Securities.
Nov 18, 2020 07:18 AM IST Now the company is expected to list its equity shares on bourses on November 20
Nov 17, 2020 02:00 PM IST In fact the premium has consistently been falling since the announcement of price band for its IPO in first week of November.
Nov 17, 2020 11:40 AM IST After the finalisation of basis of allotment, the unblocking of funds from ASBA account will take place around November 18, and shares will get credited to eligible investors around November 19.
Nov 11, 2020 10:56 AM IST On the financial front too, it is sitting with good cash levels with negligible debt levels, a good CAGR growth rate in terms of Revenue & PAT and enjoys sound margins, said Manali Bhatia of Rudra Shares
Nov 10, 2020 12:52 PM IST Geojit has come out with its report on Gland Pharma. The research firm has recommended to ''Subscribe'' the ipo in its research report as on November 07, 2020
Nov 10, 2020 12:44 PM IST Nirmal Bang has come out with its report on Gland Pharma. The research firm has recommended to ''Subscribe'' the ipo in its research report as on November 09, 2020
Nov 10, 2020 12:35 PM IST KR Choksey has come out with its report on Gland Pharma. The research firm has recommended to ''Subscribe'' the ipo in its research report as on November 09, 2020
Nov 10, 2020 12:24 PM IST Hem Securities has come out with its report on Gland Pharma. The research firm has recommended to ''Subscribe'' the ipo in its research report as on November 09, 2020
Nov 10, 2020 12:13 PM IST Gland has one of the strongest pipelines in high entry barrier injectables segment, said the brokerage.
Nov 10, 2020 08:23 AM IST ICICI Direct has come out with its report on Gland Pharma. The research firm has recommended to ''Subscribe'' the ipo in its research report as on November 09, 2020
Nov 09, 2020 12:55 PM IST Gland Pharma IPO comes at a time when global pharma industry is in a sweet spot. Should you subscribe? Let’s find out in this edition of 3-Point Analysis.
Nov 09, 2020 11:10 AM IST The Rs 6,480-crore IPO of Gland Pharma consists a fresh issue of Rs 1,250 crore and an offer for sale of over 3.48 crore equity shares by promoters and selling shareholders
Nov 09, 2020 10:00 AM IST Gland Pharma's IPO provides an opportunity to take exposure to a steady earnings compounder with strong credentials
Nov 09, 2020 07:46 AM IST The shareholding of promoters - Fosun Singapore and Shanghai Fosun Pharma - in the company will be reduced to around 58 percent from 74 percent now.
Nov 08, 2020 10:23 AM IST Gland Pharma aims to raise Rs 6,479.54 crore via public issue, of which Rs 1,943.86 crore has already been raised from anchor investors on November 6.
Nov 07, 2020 03:03 PM IST The issue will close on November 11 and equity shares are expected to list on the BSE and National Stock Exchange of India on November 20.
Nov 07, 2020 01:05 PM IST The IPO Committee of the board of directors of the company vide resolution on November 6, 2020 and the selling shareholders in consultation with the book running lead managers to the IPO have "finalised allocation of 1,29,59,089 equity shares in aggregate, to anchor investors at the anchor investor allocation price of Rs 1,500 per equity share", the company informed the BSE.
Nov 04, 2020 11:48 AM IST The IPO consists of a fresh issue of Rs 1,250 crore and an offer for sale of 3,48,63,635 equity shares by promoter and other selling shareholders.
Nov 03, 2020 10:24 PM IST Last month, Gland Pharma received approval from capital markets regulator Sebi to launch an initial public offer which included a fresh issue of Rs 1,250 crore.
